Secarna Pharmaceuticals and Vect-Horus Collaborate to Develop RNA-Targeted Therapeutics for CNS Disorders
Secarna Pharmaceuticals and Vect-Horus have formed a research collaboration to develop RNA-targeted therapeutics for central nervous system (CNS) disorders, combining Secarna's OligoCreator technology with Vect-Horus' VECTrans platform. The partnership aims to enable systemic delivery of oligonucleotide therapies across the blood-brain barrier, expanding the presence of both companies in targeted delivery and CNS indications. This collaboration has the potential to unlock new treatments for neurodegenerative and other CNS disorders, delivering solutions that impact patient lives.
Key Takeaways:
- Secarna Pharmaceuticals and Vect-Horus have entered into a strategic research collaboration to develop RNA-targeted therapeutics for CNS disorders using combined expertise in RNA therapeutics and advanced delivery technologies.
- The partnership will combine Vect-Horus' VECTrans platform with Secarna's proprietary OligoCreator oligonucleotide discovery platform to expand Secarna's targeted delivery portfolio and offer a novel approach to treating neurodegenerative diseases.
- The collaboration will unlock new potential treatments for neurodegenerative and other CNS disorders by enabling systemic delivery of oligonucleotide therapies across the blood-brain barrier.
- Secarna and Vect-Horus will work together to address the long-standing delivery challenges through the blood-brain barrier, bringing forward innovative treatment options for patients with limited and ineffective treatment options.
- Vect-Horus' VECTrans platform has been validated in multiple preclinical animal models for various diseases, including glioblastoma multiforme and pancreatic cancer.
- Secarna's AI-empowered OligoCreator platform has been designed to rapidly discover and refine highly effective and safe oligonucleotide therapies.
Statistics:
- Over 20 years of expertise in Vect-Horus' VECTrans platform.
- Multiple preclinical animal models validated for VECTrans against various diseases.
- Secarna Pharmaceuticals has a unique 'OligoCreator' platform leveraged to transform untreatable conditions into treatable ones.
- 42 employees in Vect-Horus, most in R&D.
Sources:
- Secarna Pharmaceuticals and Vect-Horus collaboration announcement.
- Martinsried, Germany, and Marseille, France, July 10 -- Secarna Pharmaceuticals issued the following news release.
- Secarna Pharmaceuticals GmbH & Co. KG and Vect-Horus collaboration press release.
- About Vect-Horus.
- About Secarna Pharmaceuticals.
- Contify.com, 2017.